Indevus Plans End-Of-Summer NDA For Nebido Following Positive Phase III Results

Specialty pharma will price the quarterly injectable hypogonadism therapy to compete with current topical treatments.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet